Vermillion Takes Control: Dx Firm Launches Its Own Lab To Market Ovarian Cancer Test
This article was originally published in The Gray Sheet
Not happy with market penetration since its FDA-cleared OVA1 ovarian cancer molecular assay launched exclusively via Quest Diagnostics in 2009, Vermillion has launched ASPiRA Labs to more directly connect with OB-GYN customers.
You may also be interested in...
Quest Diagnostics will leverage its know-how of the women's health care segment and relationships with OB/GYNs to market Vermillion's OVA1, the first FDA-cleared blood test to help assess potentially malignant ovarian tumors prior to surgery
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.
'Hunker Down, Expect The Worst And Hope For The Best:' Investment Analyst Advises Medtech Businesses To Cut Costs
Maxim Jacobs, managing partner at Edison Investment Research urges medtech companies to be financially prudent as the COVID-19 pandemic worsens. Cancellations of routine surgeries are creating a huge strain on device businesses which could continue for months.